These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 28073970

  • 1. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE, Hill A.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1243-1252. PubMed ID: 28073970
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ, Gibbert J, Wirth D, Diel R.
    Eur Respir J; 2015 Dec 01; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract] [Full Text] [Related]

  • 4. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
    BMC Infect Dis; 2019 Aug 20; 19(1):733. PubMed ID: 31429722
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R, Hittel N, Schaberg T.
    Respir Med; 2015 May 20; 109(5):632-41. PubMed ID: 25862597
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 20; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, Schechter MC, Kipiani M.
    Clin Infect Dis; 2024 Apr 10; 78(4):1043-1052. PubMed ID: 37962987
    [Abstract] [Full Text] [Related]

  • 14. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Cox V, Brigden G, Crespo RH, Lessem E, Lynch S, Rich ML, Waning B, Furin J.
    Int J Tuberc Lung Dis; 2018 Apr 01; 22(4):407-412. PubMed ID: 29562988
    [Abstract] [Full Text] [Related]

  • 15. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A.
    PLoS One; 2020 Apr 01; 15(12):e0241065. PubMed ID: 33259492
    [Abstract] [Full Text] [Related]

  • 16. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Curr Opin Pulm Med; 2018 May 01; 24(3):244-252. PubMed ID: 29470252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Expert Opin Pharmacother; 2015 May 01; 16(18):2737-50. PubMed ID: 26478945
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.
    Int J Tuberc Lung Dis; 2016 Feb 01; 20(2):177-86. PubMed ID: 26792469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.